HCM
VNDA icon

Highbridge Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Highbridge Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-18,100
Closed -$276K – 1752
2017
Q4 		$276K Buy
18,100
+3,600
+25% +$53.4K ﹤0.01% 1278
2017
Q3 		$260K Buy
+14,500
New +$243K ﹤0.01% 1278

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Highbridge Capital Management's VNDA Position: Q1 2018 in Review

Highbridge Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 52,173 shares — an estimated $793K sold.

Highbridge Capital Management first reported a position in VNDA in Q3 2013 and held it in 7 quarters. The position peaked at $2.53M in Q3 2013. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • Highbridge Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 52,173 Vanda Pharmaceuticals shares in Q1 2018, an estimated $793K.
  • Highbridge Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 7 quarters.
  • Highbridge Capital Management's Vanda Pharmaceuticals position peaked at $2.53M in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.